Top

Published in:

01-10-2021 | IgA Vasculitis | Review

IgA vasculitis

Authors: Evangéline Pillebout, Cord Sunderkötter

Published in: Seminars in Immunopathology | Issue 5/2021

Abstract

IgA vasculitis (IgAV) is an inflammation of small vessels caused by perivascular deposition of IgA and activation of neutrophils. It may present as systemic vasculitis (IgAV - Henoch-Schönlein purpura) or as a variant restricted to the skin (skin-limited IgAV), while IgA nephropathy presents a variant restricted to the kidneys. Systemic IgAV affects children more frequently than adults (150 to 200 for 1; incidence 1 in 1 million/year). In the latter, disease more often leads to chronic renal disease. The dominant clinical features include round or oval and retiform palpable purpura predominantly on the lower legs, arthralgia or arthritis, gastrointestinal bleeding or pain and glomerulonephritis with mesangial IgA deposits (IgAVN). Pulmonary, cardiac, genital and neurological involvement occurs, but is rare. Immune complexes containing galactose-deficient IgA1 play a pivotal role in the pathophysiology of IgAV; via the Fc alpha receptor (CD89), they induce neutrophilic inflammation around cutaneous vessels and mesangial proliferation and inflammation in the glomerulus. In case of self-limited disease, only symptomatic treatment is recommended. Treatment of severe IgAV, nephritis or gastrointestinal manifestations, is not established, but some studies reported a benefit of corticosteroids, combined with immunosuppressive drugs. Short-term outcome depends on the severity of gastrointestinal manifestations, while long-term prognosis depends on the severity of nephritis.

Sunderkötter CH, Zelger B, Chen K-R, Requena L, Piette W, Carlson JA, Dutz J, Lamprecht P, Mahr A, Aberer E, Werth VP, Wetter DA, Kawana S, Luqmani R, Frances C, Jorizzo J, Watts JR, Metze D, Caproni M, Alpsoy E, Callen JP, Fiorentino D, Merkel PA, Falk RJ, Jennette JC (2018) Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 70:171–184. https://doi.org/10.1002/art.40375CrossRef

Goldstein AR, White RH, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 339:280–282PubMedCrossRef

Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet 360:666–670PubMedCrossRef

Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D (2002) Henoch-Schonlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 13:1271–1278PubMedCrossRef

Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR (2002) Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360:1197–1202PubMedCrossRef

Watts RA, Lane S, Scott DG (2005) What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 19:191–207PubMedCrossRef

Penny K, Fleming M, Kazmierczak D, Thomas A (2010) An epidemiological study of Henoch-Schonlein purpura. Paediatr Nurs 22:30–35PubMedCrossRef

Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M, Gonzalez-Gay MA (1997) Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 40:859–864PubMedCrossRef

Kawasaki Y, Suyama K, Yugeta E, Katayose M, Suzuki S, Sakuma H, Nemoto K, Tsukagoshi A, Nagasawa K, Hosoya M (2010) The incidence and severity of Henoch-Schonlein purpura nephritis over a 22-year period in Fukushima Prefecture Japan. Int Urol Nephrol 42:1023–1029PubMedCrossRef

10.

Garcia-Porrua C, Calvino MC, Llorca J, Couselo JM, Gonzalez-Gay MA (2002) Henoch-Schonlein purpura in children and adults: clinical differences in a defined population. Semin Arthritis Rheum 32:149–156PubMedCrossRef

11.

Pillebout E, Jamin A, Ayari H, Housset P, Pierre M, Sauvaget V, Viglietti D, Deschenes G, Monteiro RC, Berthelot L (2017) Biomarkers of IgA vasculitis nephritis in children. PLoS One 12:e0188718PubMedPubMedCentralCrossRef

12.

Ozen, S.; Pistorio, A.; Iusan, S.M.; Bakkaloglu, A.; Herlin, T.; Brik, R.; Buoncompagni, A.; Lazar, C.; Bilge, I.; Uziel, Y.; et al. EULAR/PRINTO/PRES Criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final Classification Criteria. Ann Rheum Dis 2010, 69, 798–806.

13.

Drerup C, Hake L, Oji V, Sunderkötter C (2018) Recurrent Acute Hemorrhagic Edema of Infancy (AHEI) during puberty. J Dtsch Dermatol Ges 16:1496–1498. https://doi.org/10.1111/ddg.13699CrossRefPubMed

14.

Zhang Y, Huang X (2008) Gastrointestinal involvement in Henoch-Schönlein purpura. Scand J Gastroenterol 43:1038–1043. https://doi.org/10.1080/00365520802101861CrossRefPubMed

15.

Kaswala D, Chodos A, Ahlawat S (2016) Henoch-Schonlein purpura with gastrointestinal involvement in an adult patient. Gastroenterol Hepatol (N Y) 12:321–323

16.

Yamazaki T, Akimoto T, Iwazu Y, Sugase T, Takeshima E, Numata A, Komada T, Yoshizawa H, Otani N, Morishita Y, Saito O, Takemoto F, Muto S, Kusano E, Nagata D (2015) Henoch–Schönlein purpura complicated with severe gastrointestinal bleeding. CEN Case Rep 4:106–111. https://doi.org/10.1007/s13730-014-0148-8CrossRefPubMed

17.

Garzoni L, Vanoni F, Rizzi M, Simonetti GD, Simonetti BG, Ramelli GP, Bianchetti MG (2009) Nervous system dysfunction in Henoch-Schonlein syndrome: systematic review of the literature. Rheumatology 48:1524–1529. https://doi.org/10.1093/rheumatology/kep282CrossRefPubMed

18.

Lava SAG, Peeters GGAM, Bianchetti MG, Goeggel Simonetti B, Simonetti GD, Milani GP (2017) Posterior reversible encephalopathy syndrome in Henoch–Schönlein purpura. Rheumatol Int 37:461–463. https://doi.org/10.1007/s00296-016-3577-1CrossRefPubMed

19.

Rajagopala S, Parameswaran S, Ajmera JS, Ganesh RN, Katrevula A (2017) Diffuse alveolar hemorrhage in IgA nephropathy: case series and systematic review of the literature. Int J Rheum Dis 20:109–121PubMedCrossRef

20.

Rajagopala S, Shobha V, Devaraj U, D’Souza G, Garg I (2013) Pulmonary hemorrhage in Henoch-Schönlein purpura: case report and systematic review of the English literature. Semin Arthritis Rheum 42:391–400. https://doi.org/10.1016/j.semarthrit.2012.07.004CrossRefPubMed

21.

Chen SY, Chang KC, Yu MC, Asueh S, Ou LS (2011) Pulmonary hemorrhage associated with Henoch-Schonlein purpura in pediatric patients: case report and review of the literature. Semin Arthritis Rheum 41:305–312PubMedCrossRef

22.

Rostoker G (2001) Schonlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs 15:99–138PubMedCrossRef

23.

Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rodriguez-Ledo P, Gonzalez-Gay MA (2001) Henoch-Schonlein purpura in children from Northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 80:279–290CrossRef

24.

Saulsbury FT (1999) Henoch-Schonlein purpura in children. report of 100 patients and review of the literature. Medicine (Baltimore) 78:395–409CrossRef

25.

Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, De Martino M (2005) Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 35:143–153PubMedCrossRef

26.

Audemard-Verger A, Terrier B, Dechartres A, Chanal J, Amoura Z, Le Gouellec N, Cacoub P, Jourde-Chiche N, Urbanski G, Augusto JF et al (2017) Characteristics and Management of IgA vasculitis (Henoch-Schonlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheum 69:1862–1870CrossRef

27.

Rieu P, Noel LH (1999) Henoch-Schonlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne (Paris) 150:151–159

28.

Berthelot L, Jamin A, Viglietti D, Chemouny JM, Ayari H, Pierre M, Housset P, Sauvaget V, Hurtado-Nedelec M, Vrtovsnik F et al (2018) Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrol Dial Transplant 33(9):1579–1590PubMed

29.

Nakamoto Y, Asano Y, Dohi K, Fujioka M, Iida H, Kida H, Kibe Y, Hattori N, Takeuchi J (1978) Primary IgA glomerulonephritis and Schonlein-Henoch purpura nephritis: clinicopathological and immunohistological characteristics. Q J Med 47:495–516PubMed

30.

Davin JC, Ten Berge IJ, Weening JJ (2001) What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int 59:823–834PubMedCrossRef

31.

Droz D, Lantz B (1995) Biopsie Rénale. INSERM, Paris

32.

Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, Wang H (2013) Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 62:891–899PubMedCrossRef

33.

Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, Fervenza FC, Cattran DC (2011) Validation of the Oxford classification of IgA nephropathy. Kidney Int 80:310–317PubMedCrossRef

34.

Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, Barratt J, Suzuki Y, Sunderkötter C (2019) Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis. J Am Acad Dermatol 81:1078–1085. https://doi.org/10.1016/j.jaad.2019.03.029CrossRefPubMed

35.

Allez M, Denis B, Bouaziz J-D, Battistella M, Zagdanski A-M, Bayart J, Lazaridou I, Gatey C, Pillebout E, Chaix Baudier M-L, Delaugerre C, Molina JM, le Goff J (2020) COVID-19-related IgA vasculitis. Arthritis Rheum:72, 1952–1953. https://doi.org/10.1002/art.41428

36.

Podjasek JO, Wetter DA, Pittelkow MR, Wada DA (2012) Henoch-Schonlein purpura associated with solid-organ malignancies: three case reports and a literature review. Acta Derm Venereol 92:388–392PubMedCrossRef

37.

Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R (2014) Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schonlein purpura and primary IgA nephropathy. Pediatr Nephrol 29:1545–1551PubMedCrossRef

38.

Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K (2010) Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol 28:243–273PubMedCrossRef

39.

Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683–690PubMedCrossRef

40.

Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC (2015) Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Kidney Int 88:276–285PubMedCrossRef

41.

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196PubMedPubMedCentralCrossRef

42.

De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G, Serrazanetti D, Dalfino G, Gobbetti M et al (2015) Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 9:e99006CrossRef

43.

Chemouny, J.M.; Gleeson, P.J.; Abbad, L.; Lauriero, G.; Boedec, E.; Le Roux, K.; Monot, C.; Bredel, M.; Bex-Coudrat, J.; Sannier, A.; et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrol Dial Transplant 2018.

44.

Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117–2127PubMedCrossRef

45.

Coppo R (2018) The gut-renal connection in IgA nephropathy. Semin Nephrol 38:504–512PubMedCrossRef

46.

Coppo R (2018) The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol 33:53–61PubMedCrossRef

47.

Nadrous HF, Yu AC, Specks U, Ryu JH (2004) Pulmonary involvement in Henoch-Schonlein purpura. Mayo Clin Proc 79:1151–1157PubMed

48.

Martin SJ, Audrain MA, Baranger T, Moreau A, Dantal J, Testa A, Esnault VL (1997) Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. Am J Kidney Dis 29:125–131. https://doi.org/10.1016/s0272-6386(97)90019-6CrossRefPubMed

49.

Bollée G, Noël L-H, Suarez F, Royal V, Gilardin L, de Serre NP-M, El-Ghoul B, Lesavre P, Alyanakian M-A, Fakhouri F (2009) Pauci-immune crescentic glomerulonephritis associated with ANCA of IgA class. Am J Kidney Dis 53:1063–1067. https://doi.org/10.1053/j.ajkd.2008.10.039CrossRefPubMed

50.

Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, Ivens K, Heering PJ (2010) Is Presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis 55:259–268. https://doi.org/10.1053/j.ajkd.2009.09.031CrossRefPubMed

51.

Kelley JM, Monach PA, Ji C, Zhou Y, Wu J, Tanaka S, Mahr AD, Johnson S, McAlear C, Cuthbertson D, Carette S, Davis JC, Dellaripa PF, Hoffman GS, Khalidi N, Langford CA, Seo P, St. Clair EW, Specks U, Stone JH, Spiera RF, Ytterberg SR, Merkel PA, Edberg JC, Kimberly RP (2011) IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci 108:20736–20741. https://doi.org/10.1073/pnas.1109227109CrossRefPubMedPubMedCentral

52.

Narchi H (2005) Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920PubMedPubMedCentralCrossRef

53.

Roman C, Dima B, Muyshont L, Schurmans T, Gilliaux O (2019) Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature. Eur J Pediatr 178:1275–1281. https://doi.org/10.1007/s00431-019-03409-5CrossRefPubMed

54.

Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J (1995) Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 131:1399–1402PubMedCrossRef

55.

for the Vasculitis Clinical Research Consortium, Micheletti RG, Pagnoux C, Tamura RN, Grayson PC, McAlear CA, Borchin R, Krischer JP, Merkel PA (2020) Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials 21:362. https://doi.org/10.1186/s13063-020-04285-3CrossRefPubMedCentral

56.

Sunderkötter C, Bonsmann G, Sindrilaru A, Luger T (2005) Management of leukocytoclastic vasculitis. J Dermatol Treat 16:193–206. https://doi.org/10.1080/09546630500277971CrossRef

57.

Hahn, D.; Hodson, E.; Willis, N.; Craig, J.C. Interventions for preventing and treating kidney disease in Henoch-Schonlein purpura (HSP) (Review). The Cochrane Library 2015, 8.

58.

Kawasaki Y, Suyama K, Hashimoto K, Hosoya M (2011) Methylprednisolone pulse plus mizoribine in children with Henoch-Schonlein purpura nephritis. Clin Rheumatol 30:529–535PubMedCrossRef

59.

Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRef

60.

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157–163PubMedCrossRef

61.

KDIGO work group Chapter 11 (2012) Henoch Schonlein purpura. Kidney Int Suppl 2:218–220CrossRef

62.

Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E (2010) Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein purpura. Kidney Int 78:495–502PubMedCrossRef

63.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313PubMedCrossRef

64.

Yu MY, Kim YC, Koo HS, Chin HJ (2018) Correction: Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: a 5-year follow-up study. PLoS One 13:e0192266PubMedPubMedCentralCrossRef

65.

Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543–549PubMedCrossRef

66.

Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788–795PubMedCrossRef

67.

Zheng JN, Bi TD, Zhu LB, Liu LL (2018) Efficacy and safety of mycophenolate mofetil for IgA nephropathy: an updated meta-analysis of randomized controlled trials. Exp Ther Med 16:1882–1890PubMedPubMedCentral

68.

Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, Nicastro M, Incerti M, Goldoni M, Trivioli G et al (2017) Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schonlein). Arthritis Rheum 70:109–114CrossRef

69.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH, Adler SG, Alpers CE, Ayoub I, Bagga A, Barratt J, Caster DJ, Chan DTM, Chang A, Choo JCJ, Cook HT, Coppo R, Fervenza FC, Fogo AB, Fox JG, Gibson KL, Glassock RJ, Harris D, Hodson EM, Hoxha E, Iseki K, Jennette JC, Jha V, Johnson DW, Kaname S, Katafuchi R, Kitching AR, Lafayette RA, Li PKT, Liew A, Lv J, Malvar A, Maruyama S, Mejía-Vilet JM, Moeller MJ, Mok CC, Nester CM, Noiri E, O'Shaughnessy MM, Özen S, Parikh SM, Park HC, Peh CA, Pendergraft WF, Pickering MC, Pillebout E, Radhakrishnan J, Rathi M, Roccatello D, Ronco P, Smoyer WE, Tesař V, Thurman JM, Trimarchi H, Vivarelli M, Walters GD, Wang AYM, Wenderfer SE (2019) Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95:268–280. https://doi.org/10.1016/j.kint.2018.10.018CrossRefPubMed

70.

Cherqaoui B, Chausset A, Stephan J-L, Merlin E (2016) Intravenous immunoglobulins for severe gastrointestinal involvement in pediatric Henoch-Schönlein purpura: a French retrospective study. Arch Pediatr 23:584–590. https://doi.org/10.1016/j.arcped.2016.03.018CrossRefPubMed

71.

Donghi D, Schanz U, Sahrbacher U, Recher M, Trueb RM, Mullhaupt B, French LE, Hafner J (2009) Life-threatening or organ-impairing Henoch-Schonlein purpura: plasmapheresis may save lives and limit organ damage. Dermatology 219:167–170PubMedCrossRef

72.

Chaudhary K, Shin J-Y, Saab G, Luger AM (2008) Successful treatment of Henoch-Schonlein purpura nephritis with plasma exchange in an adult male. Clin Kidney J 1:303–306. https://doi.org/10.1093/ndtplus/sfn106CrossRef

73.

Shenoy M, Bradbury MG, Lewis MA, Webb NJ (2007) Outcome of Henoch-Schonlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722PubMedCrossRef

74.

Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, Suzuki S, Suzuki H (2004) Plasmapheresis therapy for rapidly progressive Henoch-Schonlein nephritis. Pediatr Nephrol 19:920–923PubMedCrossRef

Title: IgA vasculitis
Authors: Evangéline Pillebout
Cord Sunderkötter
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: IgA Vasculitis
IgA Vasculitis
Vasculitis
Vasculitis
Glomerulonephritis
Published in: Seminars in Immunopathology / Issue 5/2021
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-021-00874-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

The molecular mechanisms of inflammation and scarring in the kidneys of immunoglobulin A nephropathy

The immune landscape of IgA induction in the gut

Complement activation in IgA nephropathy

Are there animal models of IgA nephropathy?

The microbiome and IgA nephropathy

Is IgA nephropathy the same disease in different parts of the world?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage